News and Announcements
OncoSil Medical Interview on CE Mark and Growth Plans
- Published November 26, 2015 12:31PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th November 2015, ASX Announcement
OncoSil Medical Limited (ASX:OSL) (OncoSil Medical, the Company) is pleased to provide details of an interview with Chief Executive Officer and Managing Director Daniel Kenny and Finance News Network to discuss the Company’s CE Mark progress and growth plans.
The interview can be viewed via the OncoSil Medical company website; via this link: Media interview on CE Mark and Growth Plans
OncoSil Medical is focused on the commercialisation of its lead product candidate, the OncoSilTM localised radiation treatment for cancer. It is concurrently seeking a Conformité Européenne (CE) Mark for OncoSilTM for pancreatic and primary liver cancer (HCC), which would facilitate commercialisation in the European Union and other major markets (including Australia, Canada and Singapore), and US approval via the US FDA.
The Company was granted a Fast Track review for its CE Mark with the European regulator in October this year and expects to receive the outcome of its CE Mark application in the near future.
To read the full announcement, please click here.